Near-universal newborn screening makes the UK's 15,000-17,000-patient SCD registry unusually reliable, but the addressable market for a new agent is the 4,000-6,000-patient subset still inadequately controlled, not the total count.
The UK sickle cell disease population is sized with more confidence than almost any other rare disease in the country, for one specific reason: national newborn screening has covered SCD since 1999, so virtually every UK patient is diagnosed at birth rather than identified later through clinical presentation. The registry-based method puts the total at 15,000 to 17,000 diagnosed patients, the largest SCD population in Europe, with 350 to 500 new diagnoses a year reflecting immigration-driven demographics. That number answers the diagnosis question conclusively. It does not answer the commercial question of how many patients a new therapy could actually reach.
The treatment-adequacy method narrows the population by asking who is failing on current therapy instead of who has a diagnosis. Hydroxycarbamide reaches only about 50 percent of eligible patients under British Society for Haematology guidance, and an estimated 4,000 to 6,000 UK patients remain inadequately controlled, three or more vaso-occlusive crises a year, despite therapy. That 4,000-6,000-patient white space is the genuine addressable population for a novel non-gene agent, distinct from Casgevy's much narrower 200-300-patient-a-year gene-therapy-eligible pool. Our sensitivity analysis ranks the hydroxycarbamide adherence rate, not new-birth incidence, as the assumption most likely to move that addressable total, since incidence is stable and well-measured while adherence varies by region and prescriber.
UK sickle cell sizing — registry count versus treatment-adequacy-based estimate
| Sizing Method | Population Estimate | Source |
|---|---|---|
| Registry-based (total diagnosed) | 15,000–17,000 patients | NHS SCD Programme 2023; UK SCD Registry (WISERD) |
| Treatment-adequacy-based (hydroxycarbamide-inadequate) | 4,000–6,000 patients | British Society for Haematology hydroxycarbamide guideline; NHS SCD audit 2022 |
| Gene-therapy-eligible subset | 200–300 patients/year | NHS England SCD gene therapy planning 2024 |
Sources: NHS SCD Programme 2023; UK SCD Registry (WISERD); British Society for Haematology hydroxycarbamide guideline 2018; NHS SCD audit 2022; NHS England SCD gene therapy planning 2024.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NHS SCD Programme and UK SCD Registry (WISERD) methodology
- the newborn-screening pathway since 1999
- new-birth incidence trends and demographic concentration
Delivers
- British Society for Haematology adherence-gap data
- the treatment-adequacy sizing methodology
- how this cohort differs from Casgevy's narrower 200-300/year gene-therapy-eligible pool
Delivers
- Sensitivity ranking of every input
- why adherence rate outranks incidence as the binding near-term variable
- scenario ranges tied to adherence-improvement initiatives
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why hydroxycarbamide adherence, not diagnosis or incidence, is the assumption that determines the addressable total
- Pressure-tested against the registry-vs-treatment-adequacy gap before the rest of the model is built out
- The 15,000-17,000-patient NHS SCD Programme / WISERD registry count
- Near-universal newborn-screening diagnosis pathway since 1999
- The British Society for Haematology hydroxycarbamide adherence gap (~50%)
- The 4,000-6,000-patient inadequately-controlled white space this implies
- Three concentric populations: total registry, treatment-inadequate white space, gene-therapy-eligible pool
- Why they answer different commercial questions, not one number
- Hydroxycarbamide adherence rate ranked above new-birth incidence as the binding assumption
- Scenario ranges tied to adherence-improvement initiatives
- The full triangulated model, re-runnable with your own assumptions
- The open sizing questions your team must close before the number is used in planning
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx market sizing model triangulates at least two independent methods, registry-based and treatment-adequacy-based, before accepting a patient count. This is explicitly a sizing model (static patient count), distinct from a Patient Flow or forecasting model (dynamic revenue/uptake).
Sickle cell disease UK sizing sources: NHS SCD Programme 2023, the UK SCD Registry (WISERD), the British Society for Haematology hydroxycarbamide guideline (2018), NHS SCD audit 2022, and NHS England SCD gene therapy planning 2024.
- UK SCD registry count and newborn-screening pathway verified against NHS SCD Programme 2023 and the UK SCD Registry (WISERD)
- Hydroxycarbamide adherence gap and inadequately-controlled cohort verified against the British Society for Haematology guideline (2018) and NHS SCD audit 2022
- Gene-therapy-eligible subset verified against NHS England SCD gene therapy planning 2024
Frequently asked questions
Commission this model
AXLRx delivers rare disease market sizing models built for forecasting and strategy teams sizing the UK sickle cell disease opportunity. Custom model in 72 hours.
Specify your indication, market, and cohort definition.
AXLRx analyst confirms triangulation methods and comparator set before building.
Research-verified sizing model in 72 hours with optional analyst readout.